Biovia Call 2025.2 - Project Abstract

[project acronym]

**Applications to Biovia Call 2025.2**

* Project abstracts need to be submitted by 12:00 CET on 18 November 2025 and need to follow this template.
* A sparring session with Biovia is strongly advised prior to the submission deadline. Schedule the session so it can take place between 29/09/2025 and 13/10/2025.
* This abstract template applies to
  + R&D grant – innovative development and/or innovative research
  + ICON grant
  + cSBO grant
* This template does not apply to
  + COOCK+ and TETRA: for COOCK+ and TETRA, a pre-application needs to be submitted by 27 October 2025.
  + Feasibility study: you can submit a feasibility study at any time using the original VLAIO template.
* Submitted project abstracts will be shared with representatives of VLAIO, Biovia and with experts appointed by Biovia. They provide feedback that will be shared with the consortium by 8 December 2025. A pitch for experts is foreseen on 15, 16 or 17 December 2025 and the consortium will receive final feedback on 23 December 2025.

**Language, layout and character limits**

* The abstract should be in English.
* The structure of the document should not be changed.
* Be sure to insert the acronym of your project in the footer.
* We include character limits (see Table 2). Bear in mind that a good application does not necessarily need to reach the maximum length. Character limits are excluding spaces and pictures, but including everything else, such as (but not limited to): titles, subtitles, tables, footnotes, endnotes, references,..

Table 2: Overview of character limits

|  |  |  |
| --- | --- | --- |
|  | Sections 2-6 | Section 7 |
| Character limit | Max. 20,000 | Max. 1,800 per partner\* |

\* Definition of partner (only for character limits) = external partner (such as companies or non-profit organizations), research group or subcontractor.

# General Information

## Project Info

|  |  |
| --- | --- |
| Project acronym |  |
| Project title |  |
| Project coordinator: company name / contact person / contact e-mail |  |
| (Target) Start date and project duration |  |
| Applicable technology domains  (Indicate all that apply) | ◻ Biotechnologies ◻ Medical Technologies ◻ Digital Technologies (=electronics, photonics or ICT) |
| Applicable Biovia theme (choose the most representative option) | ◻ Value-based healthcare & efficiency of healthcare ◻ Therapeutics, diagnostics & monitoring  ◻ Prevention ◻ Sustainability |
| Are any partners in the consortium a member of another Flemish spearhead cluster? | ◻ NO / YES  If YES, please clarify here : |

## Executive summary

Maximum 1 page (excluding visuals): this executive summary should enable the jury to give feedback on your project.

## The consortium

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Partner | Organization n° | Cluster membership (\*) | Contact person | Contact email and phone | Year of establishment |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

(\*) Cluster membership: indicate the clusters of which partner is member (none, Biovia, VIL, Flanders Food, Flux50, Catalisti, De Blauwe Cluster)

Advisory committee ‘adviesraad’ (required for ICON and cSBO; optional for R&D grants):

## Estimated effort

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Organization name | Role in the project[[1]](#footnote-2) | Effort (MM) | Estimated budget (EUR) | Requested funding rate (%) | Requested funding (EUR) |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

# Healthcare/medical problem or unmet need

If a sub-heading is not relevant for your project, explain why it is not.

## Describe the healthcare or medical problem or unmet need you will try to resolve

Why did you choose this particular problem or need? Who will use your solution? Who will buy your solution?

## Does your project address a problem or need at a regional or international scale?

If the problem is international, what evidence supports your international scale claim? How will you collect such evidence?

## How will your project solve this problem or unmet need?

Describe in one sentence what solution(s) you want to research and/or develop (more details can be given in the next section).

## How will you measure the positive impact of your solution on patients and/or the healthcare system during and/or after the project?

What will you (or others) do to measure the impact of your solution on the healthcare system and/or on patients so that you can properly assess the value of your solution before it is put on the market?

## Does your project involve clinicians, organizations or end-users directly?

Who are they and how are they involved in the project? Are they Belgian or located abroad?

# What innovative solutions do you propose?

## Description of your innovations and how they solve a problem or unmet need

Provide more details on the description of section 2.3 – a list of the innovations you expect to make and how these will help solve a problem or unmet need.

## Target product profile (TPP)

List the requirements your final product needs to achieve to be commercially successful.

## Describe each partner’s contribution in the solution

Short description of who will do what in the project.

## Gaps in knowledge, technology and/or data/samples

Do you still have gaps in your project? If yes, explain how you want to solve these before the start of the project.

# Project goals and outcome

## Main goals of this project

List up to four major goals you want to achieve by the end of the project.

## Work packages and main tasks

List the main work packages you currently foresee. For each work package, list the main tasks you envision in bullet points.

## Main deliverables and milestones

List the deliverables and milestones. Describe demonstrators this project will deliver, if applicable.

# State-of-the-art and leap of knowledge

## State-of-the-art at the level of the problem or unmet need

What other solutions exist globally to solve the problem or unmet need you are addressing? Think broader than your type of technology or process.

## State-of-the-art at the level of your technical solution

What key technologies are in the global pipeline to create your solution? If you need, for instance, a sensor to measure a vital sign remotely, which competing sensors are available or in development?

## How do you go beyond the state-of-the-art at the level of your technical solution?

Where will you make the difference with respect to the state-of-the-art? What unique features of your solution exceed the current options in the market or are under development?

# Valorisation and societal/economic benefit

## Valorisation plan for the solution

Describe the steps to be taken after the project was successfully executed to ensure verification, validation, regulatory approval, market entry. Describe and/or visualize the interrelationship of the consortium partners in this valorisation path and the responsibilities for commercialization.

## Valorisation plan of company x

**Per company partner** (including non-profit organizations):

Briefly describe how your company will create added value making use of the results and the strategy you envision to be able to quantify this value in the full proposal. Present an initial quantification, if possible. Also include any required investments (e.g. equipment, buildings) and new personnel (FTE) you will have to hire to reach the market for each of these steps. This can include different products from the one valorised in the valorisation plan.

## Other benefits for Flanders

Describe any societal or environmental benefits your project might deliver.

## Summary

Rough estimation of the economic leverage factor for Flanders due to this project. Fill in the following table with a synthesis of the added value for Flanders **at project level**.

|  |  |  |
| --- | --- | --- |
|  | Impact | Added value for the funding region (EUR) |
| (Average personnel costs: **€X**)  Additional FTE from the end of the project up to five  years after the project. For therapeutics, you can consider up to 10 years after the project. This is new employment that your company will create in Flanders to bring the results  to market | Y new FTE | Y x €**X** |
| Additional investments in Flanders from the end of the project up to five years after the project | Describe type of investments   * Equipment * New R&D facility * New production facility * … | Per investment type:  € A |
| Total | | € TOTAL |

# Information on the partners

## <PARTNER 1>

Describe the current activities and/or products of the partner and provide a motivation for the participation and contribution in the project. Why is the partner important for this project (what part of the project would have to be abandoned if the partner was not part of the project?) What is the relevance / strategic importance of this project for the partner? The company is expected to comply with the terms and conditions for Undertaking in Difficulties (UID/OIM)[[2]](#footnote-3).

## …

# Terms & Conditions for a project in the context of the Biovia earmarked funding call

The abstract (a requirement for grant types R&D, ICON and cSBO) and ultimately the submission of a Full Project Proposal (FPP) within the VLAIO KRIS portal are the next phases in our Biovia earmarked funding call 2025.2. After careful evaluation, VLAIO will decide to approve the subsidy for the project.

To ensure alignment with Biovia’s strategy membership policy, the following Terms and Conditions apply to **any projects** submitted via the Biovia abstract as well as to **all consortium partners**.

## Biovia Membership Requirement for Consortium Partners

8.1.1 Membership of Biovia is subject to the Membership Conditions of Biovia (cf. Biovia Membership Registration 2025 form) and is valid for one calendar year, starting 1 January and ending 31 December the same year.

8.1.2 Membership of Biovia is not a formal requirement for consortium partners during the following phases of a project:

1. At the time of submission of intent;
2. During the activities supported by Biovia in the context of the 2025.2 earmarked funding call, such as the sparring sessions and workshops designed to improve the quality and relevance of projects;
3. At the time of submission of abstract;
4. At the time of submission of the Full Project Proposal (FPP) in the VLAIO KRIS portal;
5. At the time of approval or rejection of the subsidy by VLAIO.
   * 1. Upon approval of the project by VLAIO, a success fee of 3500 euro (excl. VAT) needs to be paid by each of the consortium partners.
     2. The success fee of 3500 euro (excl. VAT) is waived for consortium partners who are members of Biovia, on the condition that they are members of Biovia both at (1) the time of submission of Full Project Proposal (FPP) in the VLAIO KRIS portal and (2) the approval of the project by VLAIO.

Any consortium partner can become a Biovia member within 30 days after approval by VLAIO (date mentioned in the VLAIO Beslissingsbrief). If the membership is not activated after 30 days, the consortium partner will be charged the success fee of 3500 euro (excl. VAT).

## Consortium Coordination

8.2.1 The Consortium Coordinator must ensure that all partners are aware of the “Terms & Conditions for a project in the context of the Biovia earmarked funding call”. When a new partner joins the consortium, the consortium coordinator must ensure they are informed and agree to the Terms & Conditions.

## Communication & Agreement

8.3.1 The “Terms & Conditions for a project in the context of the Biovia earmarked funding call” are clearly communicated by Biovia during webinars, abstract building workshops and on the Biovia website.

Consortium partners agree to these terms upon submitting an abstract and/or upon joining a pre-existing project consortium that has already submitted an intent to submit and/or abstract.

1. Project roles: Partner, Research partner, Subcontractor [↑](#footnote-ref-2)
2. An undertaking (firm, company, organization) in difficulty is explicitly excluded from state aid. The definition and rules are outlined in the [Commission Regulation (EU) No 651/2014](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0651&from=EN) on state aid compatibility with the internal market, article 2 point 18 (p19). In Dutch: Onderneming in Moeilijkheden (see [OIM](https://www.vlaio.be/nl/subsidies-financiering/onderzoeksproject/voorwaarden/ondernemingen-moeilijkheden-komen-niet) for more details and calculation methods). [↑](#footnote-ref-3)